化疗联合西妥昔单抗治疗大肠癌肝转移效果观察

Chemotherapy Combined with Cetuximab in the Treatment of Colorectal Liver Metastases Effect Observation

目的:探讨西妥昔单抗联合化疗治疗大肠癌肝转移的疗效和不良反应。方法:对30例大肠癌肝转移患者应用西妥昔单抗联合奥沙利铂、5-FU、氟达拉宾(FA)化疗联合方案进行治疗,每周一次维持,完成6周用药,评价药物的近期疗效及毒副作用。结果:30例患者均完成西妥昔单抗连续6周用药,奥沙利铂、5-FU、FA化疗2周期,无CR病例,6例PR(20.00%),10例SD(33.33%),14例PD(46.67%),疾病控制率53.33%。本组30例患者经西妥昔单抗联合化疗后,发生1级皮疹15例,2级皮疹7例,低热4例,肝功能转氨酶升高4例,无结膜炎及腹泻发生。且骨髓毒性反应在联合应用西妥昔单抗下未增加,以上不良反应经对症处理后患者均可耐受。结论:西妥昔单抗联合化疗治疗肝转移性大肠癌近期疗效显著,可提高肿瘤对放化疗的敏感性。不良反应可以耐受。

Objective：To investigate cetuximab combined with chemotherapy for liver metastases of colorectal cancer efficacy and adverse reactions.Methods：30 patients with metastatic colorectal cancer patients with cetuximab plus oxaliplatin,5-FU,FA chemotherapy treatment program once a week to maintain,complete 6 weeks treatment,the evaluation of drug efficacy and side effects.Results：30 patients completed cetuximab treatment for 6 weeks,oxaliplatin,5-FU,FA 2 cycles of chemotherapy,patients without CR,6 cases of PR（20.00%）,10 cases of SD（33.33%）,14 cases of PD（46.67%）,disease control rate of 53.33%.The group of 30 patients with cetuximab in combination with chemotherapy,the occurrence of a rash in 15 cases,2 rash in 7 cases,fever in 4 cases,4 cases of elevated liver transaminases,no conjunctivitis and diarrhea.And bone marrow toxic reaction should not,under cetuximab increased by more than symptomatic treatment in patients with adverse reactions can be tolerated.Conclusion：Cetuximab combined with chemotherapy for metastatic colorectal cancer a significant short-term effect,can increase the sensitivity of tumor to chemotherapy.Adverse reactions can be tolerated.